Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

2025-01-30 16:45:14 ET

Takeda Pharmaceutical Company Limited (TAK)

Q3 2025 Results Conference Call

January 30, 2025 05:30 AM ET

Company Participants

Christopher O’Reilly - Head, Investor Relations

Christophe Weber - President and Chief Executive Officer

Milano Furuta - Chief Financial Officer

Andy Plump - President, R&D

Conference Call Participants

Stephen Barker - Jefferies

Hidemaru Yamaguchi - Citi

Mike Nedelcovych - TD Cowen

Hiroyuki Matsubara - Nomura Securities

Tony Ren - Macquarie

Shinichiro Muraoka - Morgan Stanley

Seiji Wakao - J.P. Morgan

Hiroshi Wada - SMBC Nikko

Kazuaki Hashiguchi - Daiwa Securities

Miki Sogi - Bernstein

Fumiyoshi Sakai - UBS

Presentation

Christopher O’Reilly

[Foreign Language]

Let me start, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and other SEC filings.

Please also refer to the important notice on Page 2 of the presentation regarding forward-looking statements and our non-IFRS financial measures, which we will also discuss during this call. Definitions of our non-IFRS measures and reconciliations with the comparable IFRS financial measures included in the appendix of the presentation, please refer to Page 2 as well for important notices. We will begin the call.

First of all, we would like to invite our CEO, Christophe Weber to comment.

Christophe Weber

Thank you, Chris. Hello, everyone, and thank you for joining us. As you might have seen from our press release, today marks an important announcement regarding our Q3 results. Milano will speak to that, and my retirement from Takeda and succession.

After 12 fulfilling years with Takeda, the Board and I have agreed on June 2026 as a date of my retirement from Takeda. I will no longer be on the Board of Takeda after June 2026. I’m very pleased to announce that the Board has selected Julie Kim, President of our U.S. business unit as my successor. Julie will be proposed as a new candidate for the Board at the ordinary General Meeting of Shareholders in June ‘26, and will then be nominated as President and CEO.

The unanimous decision to select Julie was made after a very robust multiyear process, assessing both internal and external candidates. To ensure a smooth transition, we are sharing this decision now, the timing aligned with our exciting growth outlook on potential drug launches which may start as early as the second half of 2026. It will allow us to select and nominate Julie’s successor, obviously, a key role as the U.S. represents 50% of our revenue....

Read the full article on Seeking Alpha

For further details see: